{"entity":{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IBI130 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2023-11-29: recruiting. Enrollment is planned at 182 participants. Primary completion is estimated at 2024-11-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: IBI130. Registered primary measures: Adverse events (AEs).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05923008","url":"https://clinicaltrials.gov/study/NCT05923008"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2023-11-29: recruiting. Enrollment is planned at 182 participants. Primary completion is estimated at 2024-11-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT05923008","phase":"1/2","setting":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","participation":[{"nct":"NCT05923008","source":"https://clinicaltrials.gov/study/NCT05923008","fetchedAt":"2026-10-07T16:54:00.715Z","studySha256":"4b07bfb96da0279a2e64534ff25b75237a612e760b62f85c7037f640792da364","overallStatus":"RECRUITING","lastUpdatePosted":"2023-11-29","leadSponsor":"Innovent Biologics (Suzhou) Co. Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":182,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["Australia"]}],"started":"2023-11-14","startedType":"actual","enrolled":182,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05923008/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"drug":[{"id":"ibi130","kind":"drug","name":"IBI130","route":"/drugs/ibi130/"}]}}